Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?

Posted on June 14th, 2017 by in Pharmacovigilance

The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice (more…)

Compliant Monitoring of Adverse Events

Posted on May 24th, 2017 by in Pharmacovigilance

Developing and maintaining a solid strategy for screening for adverse events is critical for every pharmaceutical company. Without one, an adverse event could be reported in scientific literature without the company knowing — and failure to report it to the regulatory authorities could result in a serious warning. (more…)

Predicting Adverse Event Risks and Gaining Insights from Disparate Data

Posted on May 17th, 2017 by in Pharma R&D

The upcoming Bio IT World Conference and Expo will feature two talks from Elsevier Life Sciences consultants, focusing on predicting adverse events in clinical trials and extracting knowledge from multiple data sets. (more…)

PV Audit by Quality: Friends or Foes?

Posted on March 9th, 2017 by in Pharmacovigilance

One of the major ways to measure the health of a Pharmacovigilance (PV) organization is to organize regular audits by experienced Quality Assurance (QA) auditors. During such audits, how open should PV be with the auditors (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5